 |
Title
|
|
|
|
Phase 
|
|
|
|
Protocol IDs
|
|
|
| |
Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer
|
|
|
|
Phase III, Phase II
|
|
|
|
HFHS 05-03
NCT00448240
|
|
| |
Docetaxel With or Without Gefitinib in Treating Patients With Metastatic or Locally Recurrent Head and Neck Cancer
|
|
|
|
Phase III
|
|
|
|
ECOG-E1302
E1302, NCT00088907
|
|
| |
Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer (Paradigm Trial)
|
|
|
|
Phase III
|
|
|
|
DFCI-04006
AVENTIS-DFCI-04006, NCT00095875, PARADIGM TRIAL
|
|
| |
Docetaxel Based Chemotherapy Plus or Minus Induction Chemotherapy to Decrease Events in Head and Neck Cancer (DeCIDE)
|
|
|
|
Phase III
|
|
|
|
IRB 13362B
NCT00117572
|
|
| |
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
|
|
|
|
Phase III
|
|
|
|
RTOG-0522
RTOG 0522, RTOG-0522, NCT00265941
|
|
| |
Phase III of Unilateral Neck Irradiation With Amifostine in Patients With SCC of the Head and Neck
|
|
|
|
Phase III
|
|
|
|
186-03
ETH136-03D, NCT00206752
|
|
| |
A Study for Patients With Head and Neck Cancer
|
|
|
|
Phase III
|
|
|
|
8431
H3E-MC-JMHR, NCT00415194
|
|
| |
Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery
|
|
|
|
Phase III
|
|
|
|
EGF102988
NCT00424255
|
|
| |
SPECTRUM: Study of Panitumumab Efficacy in Patients With Recurrent and/or Metastatic Head and Neck Cancer
|
|
|
|
Phase III
|
|
|
|
20050251
SPECTRUM, 20050251, NCT00460265
|
|
| |
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
|
|
|
|
Phase III
|
|
|
|
ECOG-E1305
E1305, NCT00588770
|
|
